Literatur
-
1 Giersiepen K. et al .Gesundheitsberichterstattung des Bundes. Heft 25 Brustkrebs. Robert Koch Institut 2005
-
2
Gerber B, Müller H, Reimer T.
Controversies in preservation of ovary function and fertility in patients with breast cancer.
Breast Cancer Res Treat.
2007;
25
, p. Epub
-
3
Savard J D, Ivers H. et al .
The association between nocturnal hot flushes and sleep in breast cancer survivors.
J Pain Symptom Manage.
2004;
27
513-522
-
4
Fink G, Barton D I, Loprizini C L. et al .
Definitions of hot flushes in breast cancer survivors.
J Pain Symptom Manage.
1998;
16
327-333
-
5
Stearns V.
Clinical update: new treatment for hot flushes.
Lancet.
2007;
369
2062-2064
-
6
Shah N R, DuBois R W.
Postmenopausal therapy and breast cancer: a systematic review and metaanalysis.
Menopause.
2005;
12
668-678
-
7
Beckman M B, Brucker W, Dören C. et al .
Konsensusempfehlungen zur Hormontherapie HRT im Klinakterium und in der Postmenopause.
TUZ Journal.
2005;
1
4-7
-
8
König K, Ortmann O.
Hormontherapie im Klimakterium und in der Postmenopause.
Ärzteblatt.
;
102 (Heft 3)
A144-A147
-
9
Collins J, Blake J M, Crosignani P G.
Breast cancer risk with postmenopausal hormonal treatment.
Human Repro Update.
2005;
11
545-560
-
10
Fallowfield L F, Edwards A. et al .
Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials.
J Clin Oncol.
2001;
19
1885-1892
-
11
Smith I D, Ebbs M. et al .
Neoadjuvant treatment of postmenopausal breast cancer with anastrazole, tamoxifen or both in combination: the Immediate Preoperative Anastrazole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
J Clin Oncol.
2005;
23
5108-5116
-
12
Holmberg L A. For the HABITS steering and data monitoring committees .
HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped.
Lancet.
2004;
363
453-455
-
13
Schoultz E von. on behalf of the Stockholm Breast Cancer Study Group .
Menopausal hormone therapy after breast cancer: The Stockholm Randomized Trial.
J Natl Cancer Inst.
2005;
97
533-535
-
14
Pollow K S, Kölbl M, Lebrecht H. et al .
Phase II-Studie zur kombinierten Exemestan- und Goserelinadjuvanztherapie mit und ohne Tibolon bei prämenopausalen Frauen mit rezeptorpositivem und nodalnegativem Mammakarzinom: ADAGIO-Studie.
Geburtshilfe Frauenheilk.
2005;
65
612-619
-
15
Beckmann M B, Braendle K, Doeren W. et al .
Hormonsubstitution nach Mammakarzinom, Konsensusempehlung der Deutschen Gesellschaft für Senologie 2002.
Frauenarzt.
2003;
44
395 ff
-
16
Stearns V, Iyengar M, Dube E.
Paroxetine controlled release in the treatment of postmenopausal hot flushes: a randomized controlled trial.
JAMA.
2003;
289
2827-2834
-
17
Stearns V, Rae J M, Morocho A. et al .
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
J Natl Cancer Inst.
2003;
95
1758-1764
-
18
Loprizini C l, Pisansky T M, Foneska R. et al .
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flushes in cancer survivors.
J Clin Oncol.
1998;
16
2377-2381
-
19
Quella S K, Loprizini C L, Sloan J.
Pilot evaluation venlafaxine for the treatment of hot flushes in men undergoing androgen ablation therapy for prostate cancer.
J Urology.
1999;
162
98-102
-
20
Loprizini C l, Sloan K J, Mailliard J A. et al .
Venlafaxine in management of hot flushes in survivors of breast cancer: a controlled trial.
Lancet.
2000;
356
2059-2063
-
21
Loprizini C l, Perez E A, Quella S K. et al .
Phase III evaluation of fluoxetine for treatment of hot flushes.
J Clin Oncol.
2002;
20
1578-1583
-
22
Pandya K J. et al .
Gabapentin for hot flushes in 420 women with breat cancer: a randomized double-blind placebo-controlled trial.
Lancet.
2005;
366
818-824
-
23
Freedman R R.
Physiology of hot flushes.
Man J Hum Biol.
2001;
13
453-464
-
24
Nagamani M, Kelver M E, Smith E R.
Treatment of menopausal hot flushes with transdermal administration of clonidin.
Am J Obstet Gynecol.
1987;
156
561-566
-
25
Pockaj B A, Loprinzi C L, Sloan J A. et al .
Pilot evaluation of black cohosh for the treatment of hot flushes in women.
Cancer Invest.
2004;
22
515-521
-
26
Jacobson J S, Troxel A B, Evans J. et al .
Randomized trial of black cohosh for the treatment of hot flushes among women with a history of breast cancer.
J Clin Oncol.
2001;
19
2739-2745
-
27
Nelson H V, Haney K K, Fu E. et al .
Nonhormonal therapies for menopausal hot flushes.
JAMA.
2006;
297
2057-2071
-
28
Harris D M, Besselink E, Henning S M. et al .
Phytoestrogens induce differential estrogen receptor alpha- or beta-mediated responses in transfected breast cancer cells.
Exp Biol Med.
2005;
230
558-568
-
29
Albertazzi P, Pansini F, Bonaccorsi G. et al .
The effect of dietary soy supplementation on hot flushes.
Obstet Gynecol.
1998;
91
6-11
-
30
McGregor C A, Canney P A, Patterson G. et al .
A randomized trial of oral soy supplements versus placebo for treastment of menopausal symptoms in patients with early breast cancer.
Eur J Cancer.
2005;
41
708-714
-
31
Cassidy A A, Lise Nielsen P, Hall I. et al .
A critical review of health effects of soyabean phyto-estrogens in post-menopausal women.
Proc Nutr Soc.
2006;
65
76-92
-
32
Wyon Y, Wijma K, Nedstrand E. et al .
A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women.
Climacteric.
2004;
7
153-164
-
33
Pritchard K I, Levine M. for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer .
14. Practice Guidelines. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer.
CMAJ.
2002;
166
1017-1022
-
34
Pritchard K I.
The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives.
Ann Oncol.
2001;
12
301-310
-
35
Gainford M C, Nguyen H, Verma S, Clemons M.
A practical guide to the management of menopausal symptoms in breast cancer patients.
Support Care Cancer.
2005;
13
573-578
-
36
Barrett-Connor E.
Hormone replacement therapy, heart diesease and other considerations.
Ann Rev Public Health.
1998;
19
55-72
-
37
Grady D, Petitti D B. et al .
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med.
1992;
117
1016-1037
-
38
Stampfer M J.
Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.
Prev Med.
1991;
20
47-63
-
39
Humphrey L L, Sox H C.
Postmenopausal hormone replacement and the primary prevention of cardiovascular disease.
Ann Int Med.
2002;
137
273-284
-
40
Nelson H D, Nygren P, Teutsch S M, Allan J D.
Postmenopausal hormone replacement therapy: scientific review.
JAMA.
2002;
288
872-881
-
41
Rossouw J E, Manson J E, Wu L. et al .
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
JAMA.
2007;
297
1465-1477
-
42
Beckmann M B, Brucker W, Dören C. et al .
Konsenus-Empfehlungen zur Hormontherapie im Klimakterium und in der Postmenopause.
.
2003;
44
138-141
-
43
WHO .
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.
World Health Organ Tech Rep Ser.
1994;
843
1-129
-
44
Hillner B E, Chlebowski R T, Gralow J. et al .
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
J Clin Oncol.
2003;
21
4042-4057
Dr. F. Horn
Klinik für Frauenheilkunde und Geburtshilfe der Universität Regensburg am Caritas-Krankenhaus St. Josef
Landshuter Str. 65
93053 Regensburg
Email: fhorn@caritasstjosef.de
